T2 Biosystems brings in $10.8M for diagnostics
T2 Biosystems, a company working to develop new diagnostic methods, received $10.8 million in second-round financing from new investors In-Q-Tel (which also helps fund the CIA, incidentally) and Partners Healthcare, and existing investors Flagship Ventures, Flybridge Capital Partners and Polaris Venture Partners.
The Cambridge, Mass.-based company plans to use the new money to develop a beta version of a device combining MRI properties and nanotechnology and to run it through a series of tests over the… Continue Reading
Life sciences briefing: Wednesday, Sept. 26, 2007
Featured companies: Ablynx, Cardiosolutions, Carigent Thereapeutics, Elusys, Genome Corp., GlobeImmune, Novazone, Targanta Therapeutics, Waterfront Media
UPDATED at 5:45am on 9/27/07
GlobeImmune raises $41M for immune-system therapies — GlobeImmune, a Louisville, Colo., biotech focused on new forms of immunotherapy to treat viral infections and cancer, raised $41.2 million in a third funding round. Investors included Wexford Capital, Celgene, the Mellon Family Investment Company, the Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, HealthCare Ventures,… Continue Reading